322MO Amivantamab in combination with lazertinib in patients with atypical epidermal growth factor receptor (EGFR) mutations excluding exon 20 insertion mutations: Initial results from CHRYSALIS-2

Byoung Chul Cho; Y. Wang; Y. Li; L. Wu; B. Besse; M.E. Marmarelis; K. Goto; Jin Sun Lee; SH Lee; Y. Zhang; J. Neal; J. Curtin; J.M. Bauml; J. Mahoney; L. Trani; R.E. Knoblauch; P. Tomasini

doi:10.1016/j.annonc.2022.10.359

322MO Amivantamab in combination with lazertinib in patients with atypical epidermal growth factor receptor (EGFR) mutations excluding exon 20 insertion mutations: Initial results from CHRYSALIS-2

Byoung Chul Cho(Yonsei University), Y. Wang(Sichuan University), Y. Li(Chongqing University), L. Wu(Hunan Cancer Hospital), B. Besse(Institut Gustave Roussy), M.E. Marmarelis(University of Pennsylvania), K. Goto(National Cancer Center Hospital East), Jin Sun Lee(Seoul National University), SH Lee(Samsung Medical Center), Y. Zhang(Zhejiang Cancer Hospital), J. Neal(Stanford Medicine), J. Curtin(Janssen (United States)), J.M. Bauml(Janssen (United States)), J. Mahoney(Janssen (United States)), L. Trani(Janssen (United States)), R.E. Knoblauch(Janssen (United States)), P. Tomasini(Centre National de la Recherche Scientifique)

Annals of Oncology

November 1, 2022

10.1016/j.annonc.2022.10.359

Cited by 4Open Access

Full Text

Abstract

Related Papers

No related papers found

Powered by citation graph analysis